NCT04283396

Brief Summary

To develop practical and effective clinical diagnosis and treatment schemes for the control of novel coronavirus pneumonia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 13, 2020

Completed
8 days until next milestone

Study Start

First participant enrolled

February 21, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 25, 2020

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2020

Completed
Last Updated

March 17, 2020

Status Verified

March 1, 2020

Enrollment Period

3 months

First QC Date

February 13, 2020

Last Update Submit

March 15, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • recovery

    Number of patients recover from novel coronavirus pneumonia

    up to 24 weeks

Interventions

systemic treatmentCOMBINATION_PRODUCT

Oxygen therapy, antiviral therapy, antibiotics, hormones, globulin

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients confirmed with novel coronavirus pneumonia.

You may qualify if:

  • Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)";

You may not qualify if:

  • Physician judged the patient was not suitable for this clinical trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Union hospital

Wuhan, Hubei, 430000, China

RECRUITING

MeSH Terms

Interventions

Neoadjuvant Therapy

Intervention Hierarchy (Ancestors)

Combined Modality TherapyTherapeutics

Central Study Contacts

Jiancai Wu

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 13, 2020

First Posted

February 25, 2020

Study Start

February 21, 2020

Primary Completion

May 30, 2020

Study Completion

July 30, 2020

Last Updated

March 17, 2020

Record last verified: 2020-03

Locations